CEO Aminov Buys 83,500 RSUs, Backing Mira’s Phase‑2 Push and Share Value
CEO Aminov’s 83,500 RSU purchase signals confidence in Mira Pharma’s Phase 2 IND push and pain‑therapy pipeline, boosting investor faith and potential price rebound.
4 minutes to read